Bruno Lucidi, previously of Idenix, Pharmasset and BMS named AgenTus CEO LEXINGTON, Mass., Oct. 23, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the launch of a subsidiary

- SHINGRIX containing QS-21 Stimulon® demonstrates remarkable efficacy of greater than 90% in pooled studies against shingles - Shingles is a major public health issue in the US, impacting as many as 1 in 3 adults over the age of 50 years LEXINGTON, Mass., Oct.

First approval for a vaccine enhanced with QS-21 Stimulon® LEXINGTON, Mass., Oct. 13, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that Health Canada granted marketing authorization

LEXINGTON, Mass., Sept. 19, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immune-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that members of the Company's Leadership will present and host one-on-one meetings at two healthcare

LEXINGTON, Mass., Sept. 13, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that GlaxoSmithKline's (GSK) shingles vaccine candidate, Shingrix, containing Agenus' proprietary immune

Earnings Conference call at 11am ET today LEXINGTON, Mass. , Aug. 3, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN ), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, provided a corporate update and reported financial results for the second

LEXINGTON, Mass., July 27, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its second quarter 2017 financial results before the market opens on Thursday, August 3, 2017.

-GSK to present the revaccination study results at the CDC's Advisory Meeting on patients who had previously received standard of care treatment- LEXINGTON, Mass., June 21, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies

LEXINGTON, Mass., June 21, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, invites investors and the general public to its Annual Meeting of Stockholders to begin at 5:00 p.m.

LEXINGTON, Mass., June 5, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the results from an ongoing Phase 1 dose-escalation trial for its anti-CTLA-4 antibody, AGEN1884, in patients

LEXINGTON, Mass., June 1, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that the Company will present at the following conferences to be held in New York City, USA: The 2017

LEXINGTON, Mass., May 22, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that an abstract on its anti-CTLA-4 antibody, AGEN1884 was accepted for poster presentation.

Substantial advances in clinical programs Update on novel differentiated preclinical programs, including cell therapy Corporate transaction resulting in $80M cash infusion and ~$70M in projected savings Earnings Conference call at 11am ET today LEXINGTON, Mass.

LEXINGTON, Mass., April 27, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its first quarter 2017 financial results before the market opens on Thursday, May 4, 2017.

First patient dosed; combination trials with anti-PD-1 plus anti-CTLA-4 antibodies planned by year-end LEXINGTON, Mass., April 20, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced

Two posters presented at AACR show evidence of ASV™ synergizing with checkpoint blockade LEXINGTON, Mass., April 5, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a clinical stage pipeline of immune checkpoint antibodies and cancer vaccines, today announced that

- Will Host Conference Call at 9am ET Today - LEXINGTON, Mass., March 30, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a clinical stage pipeline of immune checkpoint antibodies and cancer vaccines, today announced that it is reorganizing its business and

LEXINGTON, Mass., March 24, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced participation at the following conferences: The 7 th  Annual William Blair and Maidstone Life Sciences

- Will Host Update Conference Call at 11am ET Today - LEXINGTON, Mass. , March 9, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN ), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, provided a corporate update and reported financial results for

LEXINGTON, Mass., March 7, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that four abstracts on its checkpoint antibodies and cancer vaccine candidates were accepted for poster

LEXINGTON, Mass., March 2, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its fourth quarter and year end 2016 financial results before the market opens on Thursday, March 9, 2017.

Incyte secures global clinical development and commercialization responsibilities for GITR and OX40 programs, converting both from profit-sharing to royalty-bearing arrangements. Agenus to receive $80 million from Incyte: $60 million equity investment at $6 per share and $20 million in accelerated

- Appointment signals clinical focus - LEXINGTON, Mass., Jan. 30, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that Jean-Marie Cuillerot, M.D.

LEXINGTON, Mass., Jan. 17, 2017 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced a clinical trial collaboration with the National Cancer Institute (NCI).

- Third antibody from Agenus to enter the clinic this year - LEXINGTON, Mass., Nov. 30, 2016 /PRNewswire/ -- Agenus Inc. (NASDAQ:  AGEN ), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that the first patient has been dosed in a Phase